HIV 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 시험 설계별, 스폰서별, 지역별, 부문별 예측(2025-2030년)

HIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Sponsor, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

HIV 임상시험 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 HIV 임상시험 시장 규모는 2030년까지 21억 1,000만 달러에 달할 것으로 예상되며, 2025-2030년 연평균 5.8%의 성장률을 기록할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 HIV 백신 임상시험의 증가, HIV 임상시험에 대한 연구 개발 활동의 증가, HIV 감염에 대한 인식이 높아져 임상시험에 등록하는 환자 수가 증가하고 있으며, COVID-19 대유행 기간 동안 시장 성장이 멈췄습니다.

이러한 HIV/AIDS 임상시험의 감소는 COVID-19 예방을 위한 정부의 자택대기령으로 인해 임상시험이 중단되거나 지연된 데 따른 것입니다. 또한 환자 모집 중단, 임상시험 수행의 장애, HIV 임상시험에 악영향을 미치는 COVID-19 예방 백신 및 의약품 개발을 위한 신속한 연구도 포함됩니다. 그러나 임상시험 수행기관, 규제당국 및 정부기관의 전략적 조치로 이러한 영향은 크게 완화되었습니다.

WHO에 따르면 2020년에는 약 3,770만 명의 HIV 감염자가 있을 것이라고 합니다. 이 숫자를 줄이기 위해 생명공학 및 제약회사들의 자금 지원과 제휴가 증가하고 있습니다. 또한, 치료법을 찾고 이 질병에 대한 인식을 높이기 위한 정부의 노력도 증가하고 있습니다. 예를 들어, 2021년 10월 삼성바이오로직스는 Enzolytics Inc.와 파트너십을 체결했습니다. 이 제휴는 항 HIV 및 항 SARS-CoV-2 단클론항체 치료제를 생산하기 위한 것입니다.

그러나 HIV 임상시험과 예방 치료법에 대한 인식 부족이 이 시장의 성장을 저해하는 요인으로 작용하고 있으며, BioMed Central Ltd.의 유럽 보고서에 따르면 467명의 참가자 중 약 3분의 1이 HIV 감염을 인지하지 못하고 있었습니다. 결과적으로 질병에 대한 무지와 인식 부족은 HIV 임상시험 참여를 방해하는 요인으로 작용합니다.

HIV 임상시험 시장 보고서 하이라이트

• 2024년 3상이 HIV 임상시험 산업을 지배하여 30.0%의 매출 점유율을 차지했습니다. 임상 1상 시험은 다양한 투여 수준에서 약물의 안전성과 독성을 평가하고 약물의 약동학을 결정하는 데 도움이 됩니다.
• 2024년에는 중재 시험 부문이 HIV 임상시험 산업을 지배하여 69.8%의 매출 점유율을 차지할 것으로 예상됩니다.
• 2024년 제약 및 바이오 제약 기업 부문이 가장 큰 시장 점유율을 차지했습니다.
• 북미 HIV 임상시험 시장은 2024년 47.3%의 가장 큰 점유율을 차지하며 세계 시장을 장악했습니다. 이는 이 지역에서 수행되는 HIV 임상시험의 수가 증가했기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 HIV 임상시험 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 시장 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 HIV 임상시험 시장 : 단계, 추정·동향 분석

• 부문 대시보드
• 세계의 HIV 임상시험 시장 : 단계 변동 분석
• 2018-2030년의 세계 HIV 임상시험 규모와 동향 분석(단계별)
• 단계 I
• 단계 II
• 단계 III
• 단계 IV

제5장 HIV 임상시험 시장 : 시험 설계, 추정·동향 분석

• 부문 대시보드
• 세계의 HIV 임상시험 시장 : 연구 설계 변동 분석
• 2018-2030년의 세계 HIV 임상시험 규모와 동향 분석(시험 설계별)
• 개입 시험
• 관찰 시험
• 접근성 확대 시험

제6장 HIV 임상시험 시장 : 스폰서, 추정·동향 분석

• 부문 대시보드
• 세계의 HIV 임상시험 시장 : 스폰서 변동 분석
• 2018-2030년의 세계 HIV 임상시험 규모와 동향 분석(스폰서별)
• 제약·바이오의약품 기업
• 비영리 단체
• 기타

제7장 HIV 임상시험 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 기업 분류
• 기업 시장 상황 분석, 2024년
• 기업 개요
  • PPD Inc.
  • IQVIA Inc.
  • Parexel International Corporation
  • ICON plc
  • Syneos Health
  • WuXi AppTec
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Bionor Holding AS
  • Charles River Laboratories
  • GSK plc.
  • SGS SA

ksm

영문 목차

영문목차

HIV Clinical Trials Market Growth & Trends:

The global HIV clinical trials market size is estimated to reach USD 2.11 billion by 2030, registering to grow at a CAGR of 5.8% from 2025 to 2030 according to a new report by Grand View Research, Inc. The main drivers of this market are increasing HIV vaccine trials, increased R&D activities for HIV clinical trials, and rising HIV infection awareness, which leads to a large number of patients enrolling in clinical trials. During the COVID-19 pandemic, there was a halt in the market growth.

This decrease in HIV and AIDS clinical trials is due to stay-at-home orders by the government to prevent COVID-19 that led to canceled and delayed trials. It also includes disruption in patient recruitment, hurdles in the conduction of clinical trials, and rapid study for the development of vaccines and medical products for the prevention of COVID-19 that lead to detrimental effects in HIV clinical trial studies. However, these impacts were significantly reduced by adopting strategic measures taken by the clinical trial conducting organization, regulatory authorities, and government bodies.

According to the WHO, in 2020, there were around 37.7 million people infected with HIV infection. To reduce this number, increasing funding and partnerships by biotechnology and pharmaceutical firms have been observed. Moreover, increasing initiatives are being taken by the government to find treatment and spread awareness regarding this disease. For instance, in October 2021, Samsung BioLogics collaborated with Enzolytics Inc. This partnership aims to manufacture Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

However, a lack of awareness regarding HIV clinical research trials and the availability of treatments for preventing it are factors that are hindering the growth of this market. According to a report by BioMed Central Ltd. in Europe, out of 467 participants, about one-third of them were not aware of the HIV infection. As a result, ignorance and unawareness regarding the disease will prevent admission to an HIV clinical trial.

HIV Clinical Trials Market Report Highlights:

• In 2024, the phase III segment dominated the HIV clinical trials industry, accounting for a revenue share of 30.0%. Phase I studies help to assess the drug's safety & toxicity at different levels of dose & determine drug pharmacokinetics.
• In 2024, the interventional studies segment dominated the HIV clinical trials industry, accounting for a revenue share of 69.8%.
• The pharmaceutical and biopharmaceutical companies segment accounted for the largest market share in 2024.
• North America HIV clinical trials market dominated the global market in 2024 with the largest share of 47.3%. This can be attributed to the increased number of HIV clinical trials being conducted in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. HIV Clinical Trials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising drug approvals and new product launches
    • 3.2.1.2. Increasing R&D initiatives by biotechnology & pharmaceutical companies
    • 3.2.1.3. Increasing incidence of HIV
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of awareness and access to treatment for HIV Infection
    • 3.2.2.2. Stringent regulations
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. HIV Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global HIV Clinical Trials Market: Phase Movement Analysis
• 4.3. Global HIV Clinical Trials Size & Trend Analysis: by Phase, 2018 to 2030 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Phase IV
  • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global HIV Clinical Trials Market: Study Design Movement Analysis
• 5.3. Global HIV Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
• 5.4. Interventional Studies
  • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Observational Studies
  • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Expanded Access Studies
  • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Clinical Trials Market: Sponsor Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global HIV Clinical Trials Market: Sponsor Movement Analysis
• 6.3. Global HIV Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical & biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non-Profit Organizations
  • 6.5.1. Non-profit organizations market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. HIV Clinical Trials Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. PPD Inc.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. IQVIA Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Parexel International Corporation.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. ICON plc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Syneos Health
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. WuXi AppTec
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Janssen Global Services, LLC
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Gilead Sciences, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Bionor Holding AS
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Charles River Laboratories
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. GSK plc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Service benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. SGS SA
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Service benchmarking
    • 8.3.12.4. Strategic initiatives

관련자료